
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Advanced Ovarian Cancer
Case: A 54-Year-Old Woman Diagnosed With Advanced Ovarian Cancer
H & P
Imaging
Biopsy and labs:
Treatment






